# Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy

## TL;DR

This paper reviews how to manage pancreatic injury caused by immune checkpoint inhibitors, aiming to reduce unnecessary treatment interruptions and improve patient care.

## Contribution

The paper provides a clearer framework for managing immune checkpoint inhibitor-induced pancreatic injury in clinical practice.

## Key findings

- Isolated mild elevations in amylase and lipase may not always indicate clinical pancreatitis.
- Significant enzyme elevations require further investigation, including imaging.
- Consistent management strategies are needed to improve patient outcomes.

## Abstract

Background/Objectives: The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs), including pancreatic injury. While current guidelines suggest that baseline monitoring of amylase and lipase levels is not necessary, it remains common in clinical settings, leading to confusion regarding their interpretation and management. This practice may lead to confusion, especially when patients exhibit isolated mild elevations of amylase and lipase, which may not always correlate with clinical pancreatitis. In contrast, significant elevations in these enzymes warrant further investigation, including imaging to assess the presence of pancreatitis. Methods: This review aims to provide a clearer framework for clinicians in managing ICI-induced pancreatic injury, promoting consistency in practice, and improving patient outcomes by reducing unnecessary interruptions to ICI therapy. Results: It is critical to distinguish between the severity of pancreatitis to guide management. Conclusions: Considering the expected rise in the use of immune ICIs, it is crucial to increase awareness about the potential for pancreatic injury associated with these treatments.